FI119696B - BMP-11 kodande DNA-sekvenser, produktionsförfarande och användningar in vitro - Google Patents
BMP-11 kodande DNA-sekvenser, produktionsförfarande och användningar in vitro Download PDFInfo
- Publication number
- FI119696B FI119696B FI955419A FI955419A FI119696B FI 119696 B FI119696 B FI 119696B FI 955419 A FI955419 A FI 955419A FI 955419 A FI955419 A FI 955419A FI 119696 B FI119696 B FI 119696B
- Authority
- FI
- Finland
- Prior art keywords
- bmp
- seq
- sequence
- amino acid
- polypeptide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0619—Neurons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides
Claims (47)
1. En isolerad DNA-molekyl som innefattar nukleotider 375 eller 390 - 701 av sek-vensen SEQ ID No. 1. 5
2. En isolerad DNA-molekyl som innefattar nukleotider 760 eller 775 - 1086 av sekvensen SEQ ID No. 10.
3. En isolerad DNA-molekyl som innefattar en nukleotidsekvens som kodar amino-10 syror 1 eller 6 - 109 av sekvensen SEQ ID No. 2.
4. En isolerad DNA-molekyl som innefattar en nukleotidsekvens som kodar amino-syror 1 eller 6 - 109 av sekvensen SEQ ID No. 11.
5. En isolerad DNA-molekyl som innefattar en nukleotidsekvens som kodar amino- syror 1 eller 7 - 108 av sekvensen SEQ ID No. 11.
6. En DNA-sekvens som kodar ett protein med BMP-ll-aktivitet, känne- ♦ · · ; tecknad därav, att nämnda DNA-sekvens innefattar naturligt förekommande • · .:. 20 allelsekvenser och ekvivalenta degeneretiva kodonsekvenser av vilken som hälst »··· : .·. av sekvenser enligt patentkraven 1-5. • · · • ·♦ ♦ • · • · · • · ··· ·
7. En DNA-sekvens som kodar ett protein med ätminstone ett BMP-ll-aktivitet, kännetecknad därav, att nämnda DNA-sekvens hybridiseras med en sek- 25 vens komplementär till vilken som hälst av sekvenser enligt patentkraven 1 - 5 i • · stringent hybridiseringsforhällande, innefattande till exempel hybridisering vid 65 • · · °C och spolning vid 65 °C med 0,1 x SSC, 0,1 % SDS. • · · • · 1 !!! 30 BMP-11-aktivitetet är vald frän regiering av frigörelse av follikelstimulerande hor- • · • · « · · • · • · • · ·
8. En DNA-sekvens enligt patentkrav 6 eller 7, kännetecknad därav, att • · · mon, befordrande av nervcellsöverlevnad, stimulering av hematopoies och suppression av tumörutveckling i könskörtlama.
9. En DNA-sekvens enligt patentkrav 6 eller 7, kännetecknad därav, att 5 BMP-ll-aktivitet är vald frän inducering av benformation, inducering av brosk- formation, inducering av formation av nägon annan bindväv, behandling av ben-brott, reparation av medfödda huvudskäl-ansikte-defekter, reparation av huvud-skäl-ansikte-defekter orsakade av trauma, reparation av huvudskäl-ansikte-defekter orsakade av cancer, behandling av periodontal sjukdom, behandling av 10 sär, behandling av brännsär, behandling av skärsär, behandling av sämader, reparation av benbrott, behandling vid transplantationer och behandling vid tillständ med förminskad nervcellsöverlevnad.
10. En kimer DNA-molekyl, som innefattar en DNA-sekvens som kodar en pro-15 peptid ffän en medlem av TGF-B superfamiljen av proteiner som ansluts i passande läsram till en DNA-sekvens enligt vilket som heist av patentkraven 1-7.
... 11. En värdcell som är transformerad med en DNA-molekyl enligt nägot av patent- • · · . kraven 1-7. • · · · • · .:. 20
• · · · : 12. En vektor som innefattar en DNA-molekyl enligt nägot av patentkraven 1 - 7 i • · · • ·· · : .·. operativ anslutning till en expressionskontrollsekvens for denna. • · · · • · · • · · • · ·
13. En värdcell tranformerad med vektom enligt patentkrav 12. :Y: 25 • ·
14. Förfarande för producering av ett renat morfogenetiskt benprotein-11 (BMP-11), kännetecknatdärav, att förfarandetinnefattarföljandesteg: • · · • · • · · • · • · • · · (a) odling av en värdcell enligt patentkrav 11 eller 13; och • · · ::: 30 • · • · (b) ätervinning och rening av nämnda BMP-11 protein.
15. Förfarande enligt patentkrav 14, kännetecknat därav, att nänmda värdcell är transformerad med en DNA-molekyl som innefattar nukleotider 375-701 av sek-vensen SEQ ID No. 1. 5
16. Förfarande enligt patentkrav 14, kännetecknat därav, att nämnda värdcell är transformerad med en DNA-molekyl som innefattar nukleotider 760 - 1086 av sekvensen SEQ ID No. 10. 10
17. Förfarande enligt patentkrav 14, kännetecknat därav, att nämnda värdcell är transformerad med en DNA-molekyl som innefattar ekvivalenta degenerativa kodonsekvenser av nukleotider 375 - 701 av sekvensen SEQ ID No. 1.
18. Förfarande enligt patentkrav 14, kännetecknat därav, att nämnda värdcell 15 är transformerad med en DNA-molekyl som innefattar ekvivalenta degenerativa kodonsekvenser av nukleotider 760 - 1086 av sekvensen SEQ ID No. 10.
... 19. Förfarande enligt patentkrav 14, kännetecknat därav, att nämnda värdcell ♦ · · ^ . är transformerad med en DNA-molekyl som innefattar en nukleotidsekvens som ♦ · 20 kodar aminosyror 1 eller 6 - 109 av sekvensen SEQ ID No. 2.
···· • · • · · • · · ··· · : . 20. Förfarande enligt patentkrav 14, kännetecknat därav, att nämnda värdcell • · · ··· · är transformerad med en DNA-molekyl som innefattar en nukleotidsekvens som • · · kodar aminosyror 1 eller 6 - 109 av sekvensen SEQ ID No. 11. 25 • · · • ·
21. Förfarande enligt patentkrav 14, kännetecknat därav, att nämnda värdcell • · · . ·) · # är en däggdjurscell.
• · · • · • · · • · • · • · · ·. 22. Förfarande enligt patentkrav 14, kännetecknat därav, att nämnda värdcell • · · 30 ärenCHO-cell. • · • · ··♦
23. Förfarande enligt patentkrav 14, kännetecknat därav, att nänmda värdcell är en COS-l-cell.
24. Förfarande enligt patentkrav 14, kännetecknat därav, att nämnda värdcell 5 ärenCV-l-cell.
25. Förfarande enligt patentkrav 14, kännetecknat därav, att nämnda värdcell är en bakteriecell. 10
26. Förfarande enligt patentkrav 14, kännetecknat därav, att nämnda värdcell är en E. coli -cell.
27. Förfarande enligt patentkrav 14, kännetecknat därav, att nämnda värdcell är en B. subtilis -cell. 15
28. Förfarande enligt patentkrav 14, kännetecknat därav, att nämnda värdcell är en Pseudomonas-ce\\.
• · · • · · • · · ....· 29. Förfarande enligt patentkrav 14, kännetecknat därav, att nämnda värdcell • · 20 är en jästcell. ···· • * • · · • · · ··· · j .*.
30. Förfarande enligt patentkrav 14, kännetecknat därav, att nämnda värdcell • · · · . *: ·. är en insektscell. • · · 25
31. Förfarande enligt patentkrav 14, kännetecknat därav, att nämnda värdcell • · :***: är en däggdjurscell och denna DNA-molekyl innefattar vidare en DNA-sekvens som kodar en propeptid frän en medlem av TGF-β superfamiljen av proteiner, varvid • · .···. denna propeptid kodande DNA-sekvens är ansluten i passande läsram tili DNA-kod- • · · *. ningssekvensen. • Il ::: 30 • · • · • · ·
32. Förfarandeenligtpatentkrav 14, kännetecknatdärav, attförfarandetinne-fattar vidare en steg, där nämnda polypeptid dimeriseras tili en tvä underenheter innefattande homodimer, där var och en underenhet innefattar ätminstone en ami-nosyrasekvens innefattande aminosyror 1 - 108 av sekvensen SEQ ID NO. 11. 5
33. Förfarande enligt patentkrav 14, kännetecknat därav, att förfarandet innefattar vidare en steg, där renad morfogenetisk benprotein-11 (BMP-11) -polypeptid dimeriseras tili en tvä underenheter innefattande heterodimer, där den ena under-enheten innefattar en aminosyrasekvens innefattande aminosyror 1 - 109 av sek- 10 vensen SEQ ID NO. 11 och den andra underenheten innefattar en aminosyrasekvens av BMP-1.
34. Förfarande enligt patentkrav 14, kännetecknat därav, att förfarandet innefattar vidare en steg, där renad morfogenetisk benprotein-11 (BMP-11) -polypeptid 15 dimeriseras tili en tvä underenheter innefattande heterodimer, där den ena underenheten innefattar en aminosyrasekvens innefattande aminosyror 1 - 109 av sekvensen SEQ ID NO. 11 och den andra underenheten innefattar en aminosyrasek- ··. vens av BMP-2. • · · • · · • · 20
35. Förfarande enligt patentkrav 14, kännetecknat därav, att förfarandet inne- • · · · : fattar vidare en steg, där renad morfogenetisk benprotein-11 (BMP-11) -polypeptid ··· · : dimeriseras tili en tvä underenheter innefattande heterodimer, där den ena under- • · · 7 • · · · :*!*. enheten innefattar en aminosyrasekvens innefattande aminosyror 1 - 109 av sek- vensen SEQ ID NO. 11 och den andra underenheten innefattar en aminosyrasek-:*·*: 25 vensavBMP-3. • t #•0 • 0 • 0 •00 0
36. Förfarande enligt patentkrav 14, kännetecknat därav, att förfarandet inne- • 0 .·*·. fattar vidare en steg, där renad morfogenetisk benprotein-11 (BMP-11) -polypeptid • 0 0 *. dimeriseras tili en tvä underenheter innefattande heterodimer, där den ena under- 0 · 0 • · 0 /•II' 30 enheten innefattar en aminosyrasekvens innefattande aminosyror 1 - 109 av sek- • · ··· vensen SEQ ID NO. 11 och den andra underenheten innefattar en aminosyrasek-vens av BMP-4.
37. Förfarande enligt patentkrav 14, kännetecknat därav, att förfarandet inne-5 fattar vidare en steg, där renad morfogenetisk benprotein-11 (BMP-11) -polypeptid dimeriseras till en tvä underenheter innefattande heterodimer, där den ena underenheten innefattar en aminosyrasekvens innefattande aminosyror 1 - 109 av sek-vensen SEQ ID NO. 11 och den andra underenheten innefattar en aminosyrasekvens av BMP-5. 10
38. Förfarande enligt patentkrav 14, kännetecknat därav, att förfarandet innefattar vidare en steg, där renad morfogenetisk benprotein-11 (BMP-11) -polypeptid dimeriseras till en tvä underenheter innefattande heterodimer, där den ena underenheten innefattar en aminosyrasekvens innefattande aminosyror 1 - 109 av sek- 15 vensen SEQ ID NO. 11 och den andra underenheten innefattar en aminosyrasekvens av BMP-6.
39. Förfarande enligt patentkrav 14, kännetecknat därav, att förfarandet inne- • * ♦ ... j fattar vidare en steg, där renad morfogenetisk benprotein-11 (BMP-11) -polypeptid • · .;. 20 dimeriseras till en tvä underenheter innefattande heterodimer, där den ena under- ···♦ J .·. enheten innefattar en aminosyrasekvens innefattande aminosyror 1 - 109 av sek- ··· · : vensen SEQ ID NO. 11 och den andra underenheten innefattar en aminosyrasek- ··· · vens av BMP-7. • · ♦ 25
40. Förfarande enligt patentkrav 14, kännetecknat därav, att förfarandet inne- • · :***; fattar vidare en steg, där renad morfogenetisk benprotein-11 (BMP-11) -polypeptid ··· ,·.·. dimeriseras till en tvä underenheter innefattande heterodimer, där den ena under- > · · • · ···. enheten innefattar en aminosyrasekvens innefattande aminosyror 1 - 109 av sek- ···* *. vensen SEQ ID NO. 11 och den andra underenheten innefattar en aminosyrasek- • · ‘ 30 vens av BMP-8. ·»·
41. Förfarande enligt patentkrav 14, kännetecknat därav, att forfarandet inne-fattar vidare en steg, där renad morfogenetisk benprotein-11 (BMP-11) -polypeptid dimeriseras tili en tvä underenheter innefattande heterodimer, där den ena under-enheten innefattar en aminosyrasekvens innefattande amino syror 1 - 109 av sek- 5 vensen SEQ ID NO. 11 och den andra underenheten innefattar en aminosyrasekvens av BMP-9.
42. Användning av en renad morfogenetisk benprotein-11 (BMP-11) -polypeptid in vitro för regiering av frigörelse av follikelstimulerande hormon, känneteck- 10. a d därav, att polypeptiden innefattar aminosyror 1 - 109 av aminosyrasekvensen SEQ ID NO. 2.
43. Användning av en renad morfogenetisk benprotein-11 (BMP-11) -polypeptid in vitro för regiering av frigörelse av follikelstimulerande hormon, känneteck- 15. a d därav, att polypeptiden innefattar aminosyror 1 - 109 av aminosyrasekvensen SEQ ID NO. 11.
... 44. Användning av en renad morfogenetisk benprotein-11 (BMP-11) -polypeptid in • · · . vitro för stimulering av erytropoietinaktivitet, kännetecknad därav, att poly- • · 20 peptiden innefattar aminosyror 1 - 109 av aminosyrasekvensen SEQ ID NO. 2. ···· • · • · · • » · • · · · j .·.
45. Användning av en renad morfogenetisk benprotein-11 (BMP-11) -polypeptid in • · · · vitro för stimulering av erytropoietinaktivitet, kännetecknad därav, att poly-peptiden innefattar aminosyror 1 - 109 av aminosyrasekvensen SEQ ID NO. 11. :Y: 25
• · :***: 46. Användning av en renad morfogenetisk benprotein-11 (BMP-11) -polypeptid in ··· vitro för modulering av nervcellsöverlevnad, kännetecknad därav, att poly- • · · • · .1 2 3··. peptiden innefattar aminosyror 1 - 109 av aminosyrasekvensen SEQ ID NO. 2. • · · · · 2 • · · 3 • · · • · • · • · ·
47. Användning av en renad morfogenetisk benprotein-11 (BMP-11) -polypeptid in vitro för modulering av nervcellsöverlevnad, kännetecknad därav, att poly-peptiden innefattar aminosyror 1 - 109 av aminosyrasekvensen SEQ ID NO. 11. 5 • · · • · · • · · • · · · • · ··· • · · · • · • · · • · · ··· · • · • · · • · · • · · · ··« • · · • · · • · • · · • · · • · • · · • · • · M· • · • · · • · · • · • · · • · • · • · · • · · I I · ··· ··· » · » · ···
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6146493A | 1993-05-12 | 1993-05-12 | |
US6146493 | 1993-05-12 | ||
PCT/US1994/005288 WO1994026892A1 (en) | 1993-05-12 | 1994-05-12 | Bmp-11 compositions |
US9405288 | 1994-05-12 |
Publications (3)
Publication Number | Publication Date |
---|---|
FI955419A0 FI955419A0 (sv) | 1995-11-10 |
FI955419A FI955419A (sv) | 1996-01-08 |
FI119696B true FI119696B (sv) | 2009-02-13 |
Family
ID=22035966
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI955419A FI119696B (sv) | 1993-05-12 | 1995-11-10 | BMP-11 kodande DNA-sekvenser, produktionsförfarande och användningar in vitro |
Country Status (17)
Country | Link |
---|---|
US (7) | US5639638A (sv) |
EP (4) | EP1378572B1 (sv) |
JP (2) | JP3681069B2 (sv) |
KR (1) | KR100227406B1 (sv) |
AT (2) | ATE343635T1 (sv) |
AU (1) | AU678582B2 (sv) |
BR (1) | BR9406715A (sv) |
CA (1) | CA2161808C (sv) |
DE (2) | DE69434875T2 (sv) |
DK (2) | DK0698094T3 (sv) |
ES (2) | ES2274157T3 (sv) |
FI (1) | FI119696B (sv) |
HK (1) | HK1060898A1 (sv) |
NO (1) | NO320119B1 (sv) |
OA (1) | OA10191A (sv) |
PT (2) | PT1378572E (sv) |
WO (1) | WO1994026892A1 (sv) |
Families Citing this family (134)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE20004692U1 (de) | 2000-03-14 | 2001-07-26 | Sofamor Danek Gmbh | Wirbelimplantat zum Einschrauben in einen Wirbelzwischenraum |
US6150328A (en) * | 1986-07-01 | 2000-11-21 | Genetics Institute, Inc. | BMP products |
US20080139474A1 (en) * | 1991-11-04 | 2008-06-12 | David Israel | Recombinant bone morphogenetic protein heterodimers, compositions and methods of use |
AU674500B2 (en) | 1991-11-04 | 1997-01-02 | Genetics Institute, Llc | Recombinant bone morphogenetic protein heterodimers, compositions and methods of use |
US7393682B1 (en) * | 1993-03-19 | 2008-07-01 | The Johns Hopkins University School Of Medicine | Polynucleotides encoding promyostatin polypeptides |
US20030074680A1 (en) * | 1993-03-19 | 2003-04-17 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
US6465239B1 (en) * | 1993-03-19 | 2002-10-15 | The John Hopkins University School Of Medicine | Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species |
PT1378572E (pt) * | 1993-05-12 | 2007-01-31 | Genetics Inst | Composições de bmp-11 |
US6291206B1 (en) * | 1993-09-17 | 2001-09-18 | Genetics Institute, Inc. | BMP receptor proteins |
PT733109E (pt) * | 1993-12-07 | 2006-07-31 | Genetics Inst Llc | Proteinas morfogeneticas dos 0ss0s pmo-12 e pmo-13 e as suas composicoes para inducao de tendao |
US5942496A (en) | 1994-02-18 | 1999-08-24 | The Regent Of The University Of Michigan | Methods and compositions for multiple gene transfer into bone cells |
US6551618B2 (en) | 1994-03-15 | 2003-04-22 | University Of Birmingham | Compositions and methods for delivery of agents for neuronal regeneration and survival |
US7332575B2 (en) * | 1994-03-18 | 2008-02-19 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-8 nucleic acid and polypeptide from aquatic species, and transgenic aquatic species |
US5906827A (en) * | 1994-06-03 | 1999-05-25 | Creative Biomolecules, Inc. | Matrix for the manufacture of autogenous replacement body parts |
ATE305036T1 (de) * | 1994-07-08 | 2005-10-15 | Univ Johns Hopkins Med | Wachstums-differenzierungsfaktor-11 |
US20030167492A1 (en) * | 1994-07-08 | 2003-09-04 | Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a gdf-11 dominant negative polypeptide, and methods of making and using same |
US6008434A (en) | 1994-07-08 | 1999-12-28 | Johns Hopkins University School Of Medicine | Growth differentiation factor-11 transgenic mice |
US5846770A (en) * | 1994-11-22 | 1998-12-08 | Genetics Institute, Inc. | DNA molecules encoding human chordin |
US5645084A (en) * | 1995-06-07 | 1997-07-08 | Danek Medical, Inc. | Method for spinal fusion without decortication |
US5635372A (en) * | 1995-05-18 | 1997-06-03 | Genetics Institute, Inc. | BMP-15 compositions |
ATE245996T1 (de) | 1995-06-05 | 2003-08-15 | Inst Genetics Llc | Verwendung von knochenmorphogeneseproteinen zur heilung und reparatur von bindegewebebefestigung |
US5902785A (en) * | 1995-06-06 | 1999-05-11 | Genetics Institute, Inc. | Cartilage induction by bone morphogenetic proteins |
US5700774A (en) * | 1996-03-26 | 1997-12-23 | Genetics Institute, Inc. | Compositions comprising bone morphogenic proteins and truncated parathyroid hormone related peptide, and methods of inducing cartilage by administration of same |
US5965403A (en) | 1996-09-18 | 1999-10-12 | Genetics Institute, Inc. | Nucleic acids encoding bone morphogenic protein-16 (BMP-16) |
US6037519A (en) | 1997-10-20 | 2000-03-14 | Sdgi Holdings, Inc. | Ceramic fusion implants and compositions |
AU742365B2 (en) * | 1997-03-14 | 2002-01-03 | Selective Genetics, Inc. | Adenoviral vectors with modified tropism |
US7041641B2 (en) | 1997-03-20 | 2006-05-09 | Stryker Corporation | Osteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects |
US20010016646A1 (en) | 1998-03-20 | 2001-08-23 | David C. Rueger | Osteogenic devices and methods of use thereof for repair of endochondral bone, osteochondral and chondral defects |
EP1988395A1 (en) | 1997-05-30 | 2008-11-05 | Curis, Inc. | Methods for evaluating tissue morphogenesis and morphogenic activity |
US5972368A (en) * | 1997-06-11 | 1999-10-26 | Sdgi Holdings, Inc. | Bone graft composites and spacers |
US7923250B2 (en) | 1997-07-30 | 2011-04-12 | Warsaw Orthopedic, Inc. | Methods of expressing LIM mineralization protein in non-osseous cells |
CA2297489A1 (en) | 1997-07-30 | 1999-02-11 | Emory University | Novel bone mineralization proteins, dna, vectors, expression systems |
US6891082B2 (en) * | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
US6696260B1 (en) * | 1997-08-01 | 2004-02-24 | The Johns Hopkins University School Of Medicine | Methods to identify growth differentiation factor (GDF) binding proteins |
WO1999006559A1 (en) * | 1997-08-01 | 1999-02-11 | The Johns Hopkins University School Of Medicine | Methods to identify growth differentiation factor (gdf) receptors |
US20020052026A1 (en) | 1997-10-08 | 2002-05-02 | Steven M. Vicik | Methods of refolding proteins |
US6511509B1 (en) | 1997-10-20 | 2003-01-28 | Lifenet | Textured bone allograft, method of making and using same |
AU1276399A (en) * | 1997-11-07 | 1999-05-31 | Genetics Institute Inc. | Neuronal uses of bmp-11 |
US6027917A (en) | 1997-12-10 | 2000-02-22 | Genetics Institute, Inc. | Bone morphogenetic protein (BMP)-17 and BMP-18 compositions |
US20030036629A1 (en) * | 1997-12-12 | 2003-02-20 | Barry Foster | Novel tgf-beta protein purification methods |
US6004937A (en) * | 1998-03-09 | 1999-12-21 | Genetics Institute, Inc. | Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11] |
US7147839B2 (en) | 1998-05-29 | 2006-12-12 | Curis, Inc. | Methods for evaluating tissue morphogenesis and activity |
JP2002526034A (ja) * | 1998-07-28 | 2002-08-20 | ザ ジョンズ ホプキンス ユニバーシティー スクール オブ メディシン | 増殖分化因子−11 |
US6270528B1 (en) | 1998-08-06 | 2001-08-07 | Sdgi Holdings, Inc. | Composited intervertebral bone spacers |
US6849255B2 (en) * | 1998-08-18 | 2005-02-01 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods and compositions for enhancing cartilage repair |
US6727224B1 (en) * | 1999-02-01 | 2004-04-27 | Genetics Institute, Llc. | Methods and compositions for healing and repair of articular cartilage |
CA2371695A1 (en) * | 1999-04-30 | 2000-11-09 | Curis, Inc. | Morphogen-induced enhancement of fertility |
JP4672947B2 (ja) | 1999-12-06 | 2011-04-20 | ウォーソー・オーソペディック・インコーポレーテッド | 椎間板の治療装置及び方法 |
US20030082233A1 (en) * | 2000-12-01 | 2003-05-01 | Lyons Karen M. | Method and composition for modulating bone growth |
EP1341484B1 (en) | 2000-12-08 | 2009-05-06 | Osteotech, Inc. | Implant for orthopedic applications |
US6752831B2 (en) | 2000-12-08 | 2004-06-22 | Osteotech, Inc. | Biocompatible osteogenic band for repair of spinal disorders |
GB0100551D0 (en) * | 2001-01-09 | 2001-02-21 | Queen Mary & Westfield College | Protein |
US7141392B2 (en) | 2001-01-09 | 2006-11-28 | Queen Mary And Westfield College | Latent fusion protein |
TW200526779A (en) | 2001-02-08 | 2005-08-16 | Wyeth Corp | Modified and stabilized GDF propeptides and uses thereof |
EP1790726B1 (en) * | 2001-02-08 | 2013-07-03 | Wyeth LLC | Modified and stabilized GDF propeptides and uses thereof |
KR100420798B1 (ko) * | 2001-02-10 | 2004-03-02 | (주)알에이싸이언스 | 펩타이드 벡터 |
CA2449008A1 (en) * | 2001-06-01 | 2002-12-12 | Wyeth | Compositions and methods for systemic administration of sequences encoding bone morphogenetic proteins |
TWI267378B (en) * | 2001-06-08 | 2006-12-01 | Wyeth Corp | Calcium phosphate delivery vehicles for osteoinductive proteins |
US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
US6798160B2 (en) * | 2001-11-02 | 2004-09-28 | Honda Giken Kogyo Kabushiki Kaisha | Electric working machine |
WO2003045460A1 (fr) * | 2001-11-27 | 2003-06-05 | Takiron Co., Ltd. | Materiau d'implant et procede de realisation associe |
CH695985A5 (de) * | 2002-01-21 | 2006-11-15 | Straumann Holding Ag | Oberflächenmodifizierte Implantate. |
PL375045A1 (en) | 2002-02-21 | 2005-11-14 | Wyeth | Gasp1: a follistatin domain containing protein |
US7572763B2 (en) | 2002-02-21 | 2009-08-11 | Wyeth | Follistatin domain containing proteins |
US20050287135A1 (en) * | 2002-05-17 | 2005-12-29 | Wyeth | Injectable solid hyaluronic acid carriers for delivery of osteogenic proteins |
AU2003259765B2 (en) | 2002-08-13 | 2009-01-22 | Wyeth | Peptides as solubilizing excipients for transforming growth factor Beta proteins |
BR0314380A (pt) * | 2002-09-16 | 2005-07-19 | Wyeth Corp | Ativação de metaloprotease de miostatina e métodos de modulação da atividade de miostatina |
US7261893B2 (en) | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
US20040223966A1 (en) * | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
AU2004245025A1 (en) | 2003-06-02 | 2004-12-16 | Wyeth | Use of myostatin (GDF8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders |
DK1675608T3 (da) | 2003-09-12 | 2007-07-09 | Wyeth Corp | Injicerbare faste calciumphosphatstave til indgivelse af osteogene proteiner |
WO2005089829A2 (en) | 2004-03-10 | 2005-09-29 | Scil Technology Gmbh | Coated implants, their manufacturing and use thereof |
AU2005247871A1 (en) | 2004-04-27 | 2005-12-08 | Research Development Foundation | Antagonism of TGF-beta superfamily receptor signaling |
EP2298335B1 (en) | 2004-05-25 | 2014-09-03 | Stryker Corporation | Use of OP-1 for treating cartilage defects |
US7749268B2 (en) | 2004-05-26 | 2010-07-06 | Warsaw Orthopedic, Inc. | Methods for treating the spine |
AU2005272646A1 (en) * | 2004-08-12 | 2006-02-23 | Wyeth | Combination therapy for diabetes, obesity, and cardiovascular diseases using GDF-8 inhibitors |
US7473678B2 (en) | 2004-10-14 | 2009-01-06 | Biomimetic Therapeutics, Inc. | Platelet-derived growth factor compositions and methods of use thereof |
WO2006081379A1 (en) * | 2005-01-26 | 2006-08-03 | Wyeth | Use of sfrps as markers of bmp activity |
US20060240488A1 (en) * | 2005-03-23 | 2006-10-26 | Nowak John A | Detection of an immune response to GDF-8 modulating agents |
AU2006230434A1 (en) * | 2005-03-30 | 2006-10-05 | Wyeth | Methods for stimulating hair growth by administering BMPs |
US8506646B2 (en) | 2005-04-29 | 2013-08-13 | Warsaw Orthopedic, Inc. | Multi-purpose medical implant devices |
US20060247790A1 (en) * | 2005-04-30 | 2006-11-02 | Mckay William F | Shaped osteochondral grafts and methods of using same |
CA2624976A1 (en) | 2005-10-06 | 2007-04-19 | Eli Lilly And Company | Anti-myostatin antibodies |
UA92504C2 (en) | 2005-10-12 | 2010-11-10 | Эли Лилли Энд Компани | Anti-myostatin monoclonal antibody |
US8147860B2 (en) | 2005-12-06 | 2012-04-03 | Etex Corporation | Porous calcium phosphate bone material |
ES2443581T3 (es) | 2006-02-09 | 2014-02-19 | Biomimetic Therapeutics, Llc | Composiciones y métodos para el tratamiento de hueso |
EP2540310A1 (en) | 2006-05-17 | 2013-01-02 | Stryker Corporation | Methods of treating cartilage defects using a soluble morphogenic protein complex |
US9161967B2 (en) | 2006-06-30 | 2015-10-20 | Biomimetic Therapeutics, Llc | Compositions and methods for treating the vertebral column |
EP3381463A1 (en) | 2006-06-30 | 2018-10-03 | BioMimetic Therapeutics, LLC | Pdgf-biomatrix compositions and methods for treating rotator cuff injuries |
US8524265B2 (en) | 2006-08-17 | 2013-09-03 | Warsaw Orthopedic, Inc. | Medical implant sheets useful for tissue regeneration |
CA2661836A1 (en) | 2006-09-05 | 2008-03-13 | Eli Lilly And Company | Anti-myostatin antibodies |
JP2008104401A (ja) * | 2006-10-25 | 2008-05-08 | Kyoto Univ | 精原幹細胞のインビトロ増殖方法 |
AU2007234612B2 (en) | 2006-12-14 | 2013-06-27 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein stabilization formulations |
ES2447516T3 (es) | 2006-12-21 | 2014-03-12 | Stryker Corporation | Formulaciones de liberación sostenida que comprenden cristales BMP-7 |
US7678764B2 (en) | 2007-06-29 | 2010-03-16 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein formulations for use at elevated temperatures |
US8058237B2 (en) | 2007-08-07 | 2011-11-15 | Advanced Technologies & Regenerative Medicine, LLC | Stable composition of GDF-5 and method of storage |
ES2474194T3 (es) | 2008-02-13 | 2014-07-08 | Keith Hruska | PMO-7 para su uso en el tratamiento de la hiperplasia de la neo�ntima |
CN102026619A (zh) | 2008-04-14 | 2011-04-20 | 先进科技及再生医学有限责任公司 | 液体缓冲的gdf-5制剂 |
CA2735885C (en) | 2008-09-09 | 2018-08-28 | Biomimetic Therapeutics, Inc. | Platelet-derived growth factor compositions and methods for the treatment of tendon and ligament injuries |
WO2010093941A2 (en) | 2009-02-12 | 2010-08-19 | Stryker Corporation | COMPOSITIONS AND METHODS FOR MINIMALLY-INVASIVE SYSTEMIC DELIVERY OF PROTEINS INCLUDING TGF-β SUPERFAMILY MEMBERS |
JP5819733B2 (ja) | 2009-02-12 | 2015-11-24 | ストライカー コーポレイションStryker Corporation | 障害および疾患に対する全身治療のためのTGF−βスーパーファミリーメンバー含有タンパク質の末梢投与 |
WO2010110974A1 (en) | 2009-03-24 | 2010-09-30 | Stryker Corporation | Methods and compositions for tissue engineering |
US8609127B2 (en) | 2009-04-03 | 2013-12-17 | Warsaw Orthopedic, Inc. | Medical implant with bioactive material and method of making the medical implant |
US20110002897A1 (en) | 2009-06-11 | 2011-01-06 | Burnham Institute For Medical Research | Directed differentiation of stem cells |
US9399086B2 (en) | 2009-07-24 | 2016-07-26 | Warsaw Orthopedic, Inc | Implantable medical devices |
US20110224138A1 (en) | 2009-09-09 | 2011-09-15 | Julie Krop | Methods for treating pain induced by injuries and diseases of an articular joint |
AU2010295509A1 (en) | 2009-09-17 | 2012-04-19 | Stryker Corporation | Buffers for controlling the pH of bone morphogenetic proteins |
EP2516456A1 (en) | 2009-12-22 | 2012-10-31 | Stryker Corporation | Bmp-7 variants with reduced immunogenicity |
KR101959571B1 (ko) | 2010-02-22 | 2019-03-18 | 바이오미메틱 세라퓨틱스, 인크. | 건 질환의 치료를 위한 혈소판-유래 성장 인자 조성물 및 방법 |
WO2011139594A2 (en) | 2010-04-27 | 2011-11-10 | Medtronic, Inc. | Artificial bursa for intra-articular drug delivery |
KR101800596B1 (ko) | 2010-08-20 | 2017-11-22 | 와이어쓰 엘엘씨 | 디자이너 골형성 단백질 |
US9688735B2 (en) | 2010-08-20 | 2017-06-27 | Wyeth Llc | Designer osteogenic proteins |
US8998925B2 (en) | 2011-06-20 | 2015-04-07 | Rdc Holdings, Llc | Fixation system for orthopedic devices |
WO2012177759A1 (en) | 2011-06-20 | 2012-12-27 | Rdc Holdings, Llc | System and method for repairing joints |
US9434779B2 (en) * | 2012-03-19 | 2016-09-06 | The Brigham And Women's Hospital, Inc. | Growth differentiation factor 11 (GDF-11) for treatment of diastolic heart failure |
US10034945B2 (en) | 2012-07-13 | 2018-07-31 | Trustees Of Tufts College | Silk powder compaction for production of constructs with high mechanical strength and stiffness |
US20160120945A1 (en) * | 2013-02-15 | 2016-05-05 | The Brigham And Women's Hospital, Inc. | Thymic Regeneration |
JP2016518357A (ja) | 2013-04-08 | 2016-06-23 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 骨格筋幹細胞を若返らせる方法および組成物 |
US9572912B2 (en) | 2013-04-19 | 2017-02-21 | Theracell, Inc. | Demineralized bone fibers having controlled geometry and shapes and methods thereof |
WO2015070076A2 (en) * | 2013-11-08 | 2015-05-14 | President And Fellows Of Harvard College | Methods and compositions for rejuvenating neuromuscular junctions |
WO2015073396A1 (en) | 2013-11-12 | 2015-05-21 | The Brigham And Women's Hospital, Inc. | Growth differentiation factor (gdf) for treatment of diastolic heart failure |
WO2016123583A1 (en) | 2015-01-29 | 2016-08-04 | Theracell, Inc. | Demineralized bone fiber composition for use in minimally invasive surgery |
KR20170138436A (ko) | 2015-03-17 | 2017-12-15 | 이스티튜토 바이오키미코 이탈리아노 지오바니 로렌치니 에스.피.에이. | 골 형성 단백질 (bpm)의 정제 |
CN107683130B (zh) | 2015-06-17 | 2022-03-04 | 华沙整形外科股份有限公司 | 包括氧固醇的植入物和使用方法 |
EP3821880A1 (en) | 2015-10-26 | 2021-05-19 | President and Fellows of Harvard College | Oxidized polysaccharides and methods of use thereof |
CN109310742B (zh) | 2016-01-06 | 2022-12-02 | 哈佛学院校长同事会 | 使用gdf11的治疗防止体重增加、提高葡萄糖耐量并减轻脂肪肝 |
KR101810385B1 (ko) * | 2016-02-04 | 2017-12-20 | 주식회사 강스템바이오텍 | Gdf11을 포함하는 조성물 및 그의 용도 |
US10688222B2 (en) | 2016-11-21 | 2020-06-23 | Warsaw Orthopedic, Inc. | Lyophilized moldable implants containing an oxysterol |
US10639157B2 (en) | 2017-03-14 | 2020-05-05 | Theracell, Inc. | Demineralized bone fiber composition for use in minimally invasive surgery |
US11464888B2 (en) | 2017-06-12 | 2022-10-11 | Warsaw Orthopedic, Inc. | Moldable formulations containing an oxysterol in an acellular tissue matrix |
KR101893339B1 (ko) * | 2017-09-19 | 2018-08-31 | 주식회사 강스템바이오텍 | Gdf11을 포함하는 조성물 및 그의 용도 |
US11103618B2 (en) | 2018-02-22 | 2021-08-31 | Warsaw Orthopedic, Inc. | Demineralized bone matrix having improved handling characteristics |
CN109097425B (zh) * | 2018-08-28 | 2022-06-07 | 浙江康嘉基因技术有限公司 | 一种多肽及用作流感疫苗免疫佐剂的用途 |
US11498880B2 (en) | 2019-07-26 | 2022-11-15 | Warsaw Orthopedic, Inc. | Calcium phosphate granules and methods of making them |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
EP0105014B1 (en) | 1982-09-24 | 1992-05-20 | THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce | Repair of tissue in animals |
US4588684A (en) | 1983-04-26 | 1986-05-13 | Chiron Corporation | a-Factor and its processing signals |
NZ210699A (en) | 1984-01-04 | 1989-06-28 | Int Genetic Eng | Isolation of an osteogenic protein of the p3 immunologically related family |
ZA848495B (en) | 1984-01-31 | 1985-09-25 | Idaho Res Found | Production of polypeptides in insect cells |
CA1341617C (en) | 1984-06-08 | 2011-06-28 | Henry George Burger | Inhibin isolated from ovarian follicular fluid |
IL75725A (en) | 1984-07-06 | 1993-02-21 | Sandoz Ag | Recombinant human gm-csf |
DE3588058T3 (de) | 1984-07-16 | 2005-04-07 | Celtrix Pharmaceuticals, Inc., Palo Alto | Knorpel-induzierende Polypeptid-Faktoren aus Knochen |
DE3586386T2 (de) | 1984-10-05 | 1993-01-14 | Genentech Inc | Dna, zellkulturen und verfahren zur sekretion von heterologen proteinen und periplasmische proteinrueckgewinnung. |
US4740587A (en) * | 1985-07-18 | 1988-04-26 | The Salk Institute For Biological Studies | Inhibin and method of purifying same |
US4798885A (en) | 1986-02-07 | 1989-01-17 | Genentech, Inc. | Compositions of hormonally active human and porcine inhibin containing an α chain and 62 chain |
US5089396A (en) * | 1985-10-03 | 1992-02-18 | Genentech, Inc. | Nucleic acid encoding β chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid |
US5215893A (en) * | 1985-10-03 | 1993-06-01 | Genentech, Inc. | Nucleic acid encoding the ba chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid |
NZ217727A (en) * | 1985-10-03 | 1990-05-28 | Genentech Inc | Nucleic acid encoding alpha or b chain of inhibin, its production and compositions containing it |
US4737578A (en) * | 1986-02-10 | 1988-04-12 | The Salk Institute For Biological Studies | Human inhibin |
IL83003A (en) * | 1986-07-01 | 1995-07-31 | Genetics Inst | Factors that soak bone formation |
US5106748A (en) | 1986-07-01 | 1992-04-21 | Genetics Institute, Inc. | Dna sequences encoding 5 proteins |
ZA874681B (en) | 1986-07-01 | 1988-04-27 | Genetics Inst | Novel osteoinductive factors |
US5108922A (en) | 1986-07-01 | 1992-04-28 | Genetics Institute, Inc. | DNA sequences encoding BMP-1 products |
US5013649A (en) | 1986-07-01 | 1991-05-07 | Genetics Institute, Inc. | DNA sequences encoding osteoinductive products |
US5187076A (en) | 1986-07-01 | 1993-02-16 | Genetics Institute, Inc. | DNA sequences encoding BMP-6 proteins |
US5041538A (en) * | 1987-08-28 | 1991-08-20 | The Salk Institute For Biological Studies | Mammalian follistatin |
US5168150A (en) | 1988-03-17 | 1992-12-01 | Electronique Serge Dassault | Device for the processing of a magnetic-track ticket, especially an air transport ticket |
US5071834A (en) | 1988-09-16 | 1991-12-10 | Genentech, Inc. | Purified activin B composition |
US5166190A (en) * | 1990-01-08 | 1992-11-24 | Genentech, Inc. | Method for increasing fertility in males |
JPH06500991A (ja) * | 1990-05-16 | 1994-01-27 | ジェネティックス・インスティテュート・インコーポレイテッド | 骨および軟骨誘導蛋白質 |
US5168050A (en) * | 1990-05-24 | 1992-12-01 | Genentech, Inc. | Mammalian expression of the bone morphogenetic protein-2b using bmp2a/bmp2b fusion |
WO1992005199A1 (en) * | 1990-09-26 | 1992-04-02 | Genetics Institute, Inc. | Bmp-5 derivatives |
WO1992009697A1 (en) * | 1990-11-30 | 1992-06-11 | Celtrix Laboratories, Inc. | USE OF A BONE MORPHOGENETIC PROTEIN IN SYNERGISTIC COMBINATION WITH TGF-β FOR BONE REPAIR |
US5208219A (en) | 1991-02-14 | 1993-05-04 | Celtrix Pharmaceuticals Inc. | Method for inducing bone growth |
AU662155B2 (en) * | 1991-05-10 | 1995-08-24 | Celtrix Pharmaceuticals, Inc. | Targeted delivery of bone growth factors |
CA2108770C (en) * | 1991-06-25 | 2007-04-03 | John M. Wozney | Bmp-9 compositions |
US5171579A (en) * | 1991-10-11 | 1992-12-15 | Genetics Institute, Inc. | Formulations of blood clot-polymer matrix for delivery of osteogenic proteins |
AU674500B2 (en) * | 1991-11-04 | 1997-01-02 | Genetics Institute, Llc | Recombinant bone morphogenetic protein heterodimers, compositions and methods of use |
CA2141554C (en) | 1992-07-31 | 2003-02-11 | David C. Rueger | Morphogen-induced nerve regeneration and repair |
EP0690873B1 (en) | 1993-03-19 | 2003-06-11 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
PT1378572E (pt) * | 1993-05-12 | 2007-01-31 | Genetics Inst | Composições de bmp-11 |
JPH09501305A (ja) * | 1993-05-12 | 1997-02-10 | ジェネティックス・インスティテュート・インコーポレイテッド | Bmp−10組成物 |
KR100329409B1 (ko) * | 1993-08-26 | 2002-03-20 | 브루스 엠. 에이센, 토마스 제이 데스로저 | 인간 골 형태발생 단백질을 사용한 신경 재생법 |
ATE305036T1 (de) * | 1994-07-08 | 2005-10-15 | Univ Johns Hopkins Med | Wachstums-differenzierungsfaktor-11 |
US5545616A (en) * | 1994-09-22 | 1996-08-13 | Genentech, Inc. | Method for predicting and/or preventing preterm labor |
DE69723429T3 (de) | 1996-03-22 | 2007-09-20 | Curis, Inc., Cambridge | Verfahren zur verbesserten funktionellen Erholung der motorischen Koordination, der Sprache oder Sinneswahrnehmung nach Trauma oder Ischämie des ZNS |
JP3361278B2 (ja) | 1997-12-26 | 2003-01-07 | シャープ株式会社 | 反射型液晶表示装置とその製造方法、ならびに回路基板の製造方法 |
US6004937A (en) * | 1998-03-09 | 1999-12-21 | Genetics Institute, Inc. | Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11] |
-
1994
- 1994-05-12 PT PT03021107T patent/PT1378572E/pt unknown
- 1994-05-12 WO PCT/US1994/005288 patent/WO1994026892A1/en active IP Right Grant
- 1994-05-12 KR KR1019950704836A patent/KR100227406B1/ko not_active IP Right Cessation
- 1994-05-12 JP JP52569894A patent/JP3681069B2/ja not_active Expired - Fee Related
- 1994-05-12 ES ES03021107T patent/ES2274157T3/es not_active Expired - Lifetime
- 1994-05-12 EP EP03021107A patent/EP1378572B1/en not_active Expired - Lifetime
- 1994-05-12 AT AT03021107T patent/ATE343635T1/de active
- 1994-05-12 DK DK94917361T patent/DK0698094T3/da active
- 1994-05-12 DK DK03021107T patent/DK1378572T3/da active
- 1994-05-12 AT AT94917361T patent/ATE258984T1/de active
- 1994-05-12 EP EP10181708A patent/EP2272959A1/en not_active Withdrawn
- 1994-05-12 ES ES94917361T patent/ES2213745T3/es not_active Expired - Lifetime
- 1994-05-12 CA CA002161808A patent/CA2161808C/en not_active Expired - Fee Related
- 1994-05-12 PT PT94917361T patent/PT698094E/pt unknown
- 1994-05-12 AU AU69105/94A patent/AU678582B2/en not_active Ceased
- 1994-05-12 EP EP94917361A patent/EP0698094B1/en not_active Expired - Lifetime
- 1994-05-12 EP EP06022258A patent/EP1770161A3/en not_active Withdrawn
- 1994-05-12 DE DE69434875T patent/DE69434875T2/de not_active Expired - Lifetime
- 1994-05-12 DE DE69433530T patent/DE69433530T2/de not_active Expired - Lifetime
- 1994-05-12 BR BR9406715A patent/BR9406715A/pt not_active Application Discontinuation
- 1994-05-20 US US08/247,907 patent/US5639638A/en not_active Expired - Lifetime
-
1995
- 1995-05-30 US US08/452,772 patent/US5700911A/en not_active Expired - Lifetime
- 1995-11-08 NO NO19954492A patent/NO320119B1/no not_active IP Right Cessation
- 1995-11-10 OA OA60735A patent/OA10191A/en unknown
- 1995-11-10 FI FI955419A patent/FI119696B/sv not_active IP Right Cessation
-
1997
- 1997-08-28 US US08/919,850 patent/US6437111B1/en not_active Expired - Fee Related
-
1999
- 1999-10-07 US US09/414,234 patent/US6340668B1/en not_active Expired - Fee Related
-
2001
- 2001-12-20 US US10/029,016 patent/US20030083252A1/en not_active Abandoned
-
2002
- 2002-07-05 US US10/188,886 patent/US7175997B2/en not_active Expired - Fee Related
-
2004
- 2004-05-27 HK HK04103794A patent/HK1060898A1/xx not_active IP Right Cessation
- 2004-08-24 JP JP2004243948A patent/JP2005046155A/ja active Pending
-
2006
- 2006-04-11 US US11/401,228 patent/US20060172391A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI119696B (sv) | BMP-11 kodande DNA-sekvenser, produktionsförfarande och användningar in vitro | |
AU677849B2 (en) | BMP-10 compositions | |
US5932216A (en) | Antibodies to bone morphogenetic protein-10 (BMP-10) | |
US5728679A (en) | BMP-15 compositions | |
CA2265508C (en) | Bone morphogenetic protein-16 (bmp-16) compositions | |
AU763470B2 (en) | Bone morphogenetic protein (BMP)-17 and BMP-18 compositions | |
CA2574929C (en) | Bone morphogenetic protein (bmp)-17 and bmp-18 and compositions | |
AU763300B2 (en) | Bone morphogenetic protein-16 (BMP-16) compositions | |
EP0998558A1 (en) | Wa545 compositions | |
MXPA00000820A (en) | Wa545 compositions | |
MXPA00005709A (en) | Bone morphogenetic protein (bmp)-17 and bmp-18 compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Patent granted |
Ref document number: 119696 Country of ref document: FI |
|
MM | Patent lapsed |